+

WO2010073248A3 - Signature d'expression génétique pour la classification de tissu provenant d'échantillons tumoraux - Google Patents

Signature d'expression génétique pour la classification de tissu provenant d'échantillons tumoraux Download PDF

Info

Publication number
WO2010073248A3
WO2010073248A3 PCT/IL2009/001212 IL2009001212W WO2010073248A3 WO 2010073248 A3 WO2010073248 A3 WO 2010073248A3 IL 2009001212 W IL2009001212 W IL 2009001212W WO 2010073248 A3 WO2010073248 A3 WO 2010073248A3
Authority
WO
WIPO (PCT)
Prior art keywords
classification
origin
tissue
gene expression
tumor samples
Prior art date
Application number
PCT/IL2009/001212
Other languages
English (en)
Other versions
WO2010073248A2 (fr
Inventor
Ranit Aharonov
Nitzan Rosenfeld
Shai Rosenwald
Original Assignee
Rosetta Genomics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd. filed Critical Rosetta Genomics Ltd.
Priority to CN200980157378XA priority Critical patent/CN102333888B/zh
Publication of WO2010073248A2 publication Critical patent/WO2010073248A2/fr
Publication of WO2010073248A3 publication Critical patent/WO2010073248A3/fr
Priority to IL212979A priority patent/IL212979A/en
Priority to US13/167,489 priority patent/US8802599B2/en
Priority to US13/856,190 priority patent/US9096906B2/en
Priority to US14/320,113 priority patent/US20140315739A1/en
Priority to US14/746,487 priority patent/US20150368724A1/en
Priority to US15/853,258 priority patent/US20180127835A1/en
Priority to US15/909,145 priority patent/US20190032142A1/en
Priority to US16/226,406 priority patent/US20190241966A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Microbiology (AREA)
  • Bioethics (AREA)
  • General Engineering & Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Biochemistry (AREA)
  • Signal Processing (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé pour la classification de cancers et de tissus d'origine par l'analyse de profils d'expression de micro-ARN spécifiques et de molécules d'acide nucléique qui y sont associées. La classification selon un cadre d'expression basée sur un arbre des micro-ARN permet l'optimisation de traitement, et la détermination de thérapie spécifique.
PCT/IL2009/001212 2007-03-27 2009-12-23 Signature d'expression génétique pour la classification de tissu provenant d'échantillons tumoraux WO2010073248A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN200980157378XA CN102333888B (zh) 2008-12-24 2009-12-23 用于肿瘤样本起源组织分类的基因表达签名
IL212979A IL212979A (en) 2008-12-24 2011-05-18 Gene expression signature to classify the source tissue of cancer tumor samples
US13/167,489 US8802599B2 (en) 2007-03-27 2011-06-23 Gene expression signature for classification of tissue of origin of tumor samples
US13/856,190 US9096906B2 (en) 2007-03-27 2013-04-03 Gene expression signature for classification of tissue of origin of tumor samples
US14/320,113 US20140315739A1 (en) 2007-03-27 2014-06-30 Gene expression signature for classification of tissue of origin of tumor samples
US14/746,487 US20150368724A1 (en) 2007-03-27 2015-06-22 Methods and materials for classification of tissue of origin of tumor samples
US15/853,258 US20180127835A1 (en) 2007-03-27 2017-12-22 Gene expression signature for classification of tissue of origin of tumor samples
US15/909,145 US20190032142A1 (en) 2007-03-27 2018-03-01 Methods and materials for classification of tissue of origin of tumor samples
US16/226,406 US20190241966A1 (en) 2007-03-27 2018-12-19 Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14064208P 2008-12-24 2008-12-24
US61/140,642 2008-12-24

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
US12/532,940 Continuation-In-Part US20100178653A1 (en) 2007-03-27 2008-03-20 Gene expression signature for classification of cancers
PCT/IL2008/000396 Continuation-In-Part WO2008117278A2 (fr) 2007-03-27 2008-03-20 Signature d'une expression génique permettant la classification des cancers
US53294009A Continuation-In-Part 2007-03-27 2009-09-24
PCT/IL2011/000849 Continuation-In-Part WO2012070037A2 (fr) 2007-03-27 2011-11-01 Procédés et matériaux pour la classification de tissus originaires d'échantillons tumoraux

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/167,489 Continuation-In-Part US8802599B2 (en) 2007-03-27 2011-06-23 Gene expression signature for classification of tissue of origin of tumor samples

Publications (2)

Publication Number Publication Date
WO2010073248A2 WO2010073248A2 (fr) 2010-07-01
WO2010073248A3 true WO2010073248A3 (fr) 2010-09-16

Family

ID=42288202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/001212 WO2010073248A2 (fr) 2007-03-27 2009-12-23 Signature d'expression génétique pour la classification de tissu provenant d'échantillons tumoraux

Country Status (2)

Country Link
CN (1) CN102333888B (fr)
WO (1) WO2010073248A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096906B2 (en) 2007-03-27 2015-08-04 Rosetta Genomics Ltd. Gene expression signature for classification of tissue of origin of tumor samples
EP2291553A4 (fr) 2008-05-28 2011-12-14 Genomedx Biosciences Inc Systèmes et procédés de discrimination basée sur l expression d états pathologiques cliniques distincts dans le cancer de la prostate
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
EP3831954A3 (fr) 2008-11-17 2021-10-13 Veracyte, Inc. Procédés et compositions de profilage moléculaire pour le diagnostic de maladies
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2011154008A1 (fr) * 2010-06-11 2011-12-15 Rigshospitalet Classification de micro-arn de néoplasie folliculaire de la thyroïde
WO2012010584A1 (fr) * 2010-07-20 2012-01-26 Febit Holding Gmbh Ensembles de miarn complexes en tant que nouveaux biomarqueurs pour le cancer gastrique
EP2772550B1 (fr) 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Micro-ARN comme biomarqueurs pour différencier des néoplasmes de thyroïde bénins et malins
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2643479B1 (fr) * 2010-11-22 2017-09-13 Rosetta Genomics Ltd Procédés et matériaux pour la classification de tissus originaires d'échantillons tumoraux
EP2505663A1 (fr) 2011-03-30 2012-10-03 IFOM Fondazione Istituto Firc di Oncologia Molecolare Procédé pour identifier des individus asymptomatiques à haut risque touchés par un cancer du poumon à l'état précoce au moyen de la détection d'ARNmi dans les liquides corporels
CN103764844A (zh) * 2011-03-28 2014-04-30 罗塞塔金诺米克斯有限公司 用于肺癌分类的方法
WO2012145129A2 (fr) * 2011-04-18 2012-10-26 Cornell University Sous-typage moléculaire, pronostic et traitement du cancer de la prostate
WO2012161124A1 (fr) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 Composition contenant un micro arn ou système d'expression associé
US8831327B2 (en) 2011-08-30 2014-09-09 General Electric Company Systems and methods for tissue classification using attributes of a biomarker enhanced tissue network (BETN)
EP2794881B1 (fr) * 2011-12-22 2018-06-27 InteRNA Technologies B.V. Miarn pour le traitement du cancer de la tête et du cou
EP2653558B1 (fr) * 2012-04-18 2015-10-07 Roche Diagniostics GmbH Procédé de détection de cibles d'acide nucléique à l'aide d'un classificateur statistique
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3215170A4 (fr) 2014-11-05 2018-04-25 Veracyte, Inc. Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (fr) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Sous-typage moléculaire, pronostic et traitement du cancer de la vessie
CA3055925A1 (fr) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour predire la reponse a une therapie hormonale
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
JP7431760B2 (ja) * 2018-06-30 2024-02-15 ２０／２０ ジェネシステムズ，インク 癌分類子モデル、機械学習システム、および使用方法
CN110706749B (zh) * 2019-09-10 2022-06-10 至本医疗科技（上海）有限公司 一种基于组织器官分化层次关系的癌症类型预测系统和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059005A1 (en) * 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
US20060084056A1 (en) * 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20070083945A1 (en) * 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083945A1 (en) * 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
US20050059005A1 (en) * 2001-09-28 2005-03-17 Thomas Tuschl Microrna molecules
US20060084056A1 (en) * 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHULTZ ET AL.: "MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorageindependent growth.", CELL RES., vol. 18, no. 5, May 2008 (2008-05-01), pages 549 - 57 *

Also Published As

Publication number Publication date
CN102333888B (zh) 2013-07-10
WO2010073248A2 (fr) 2010-07-01
CN102333888A (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
WO2010073248A3 (fr) Signature d'expression génétique pour la classification de tissu provenant d'échantillons tumoraux
WO2008117278A3 (fr) Signature d'une expression génique permettant la classification des cancers
WO2012070037A3 (fr) Procédés et matériaux pour la classification de tissus originaires d'échantillons tumoraux
AR061136A1 (es) Procedimiento
EP3106168A3 (fr) Ciblage des microarn mir-409-5p, mir-379 et mir-154* pour traiter la métastase osseuse du cancer de la prostate et le cancer du poumon résistant aux médicaments
EP1961827A3 (fr) Procédés épigénétiques et acides nucléiques pour la détection de troubles cellulaires proliférables du sein
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
EP2198021A4 (fr) Ebi3, dlx5, nptx1 et cdkn3 pour des gènes cibles de thérapie et de diagnostic de cancer de poumon
WO2009153775A3 (fr) Procédés permettant de différencier différents types de cancers du poumon
EP1549660A4 (fr) Inhibition a mediation par l'interference par l'arn de l'expression genique de la proteine de liaison 2 associee a grb2 (gab2) au moyen de petits fragments d'acides nucleiques interferants (sina)
WO2013158309A3 (fr) Ciblage génique non disruptif
WO2010022166A3 (fr) Micro-arn (arnmi) et neurofibromatose de type 1 : un rôle en diagnostic et thérapie
WO2003070884A3 (fr) Inhibition de l'expression du gene de la mdr p-glycoproteine induite par l'interference d'arn, au moyen d'acide nucleique interferant court (sina)
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
WO2008079269A3 (fr) Nouveaux procédés pour une analyse fonctionnelle de données expérimentales à haut débit et groupes de gènes identifiés à partir de ceux-ci
WO2011057034A3 (fr) Catenae : cellules souches cancéreuses des séreuses
EP2272453A4 (fr) Système thérapeutique, instrument thérapeutique et procédé de traitement énergétique de tissus vivants
EP2647711A3 (fr) Voies d'export alternatives pour l'interférence d'ARN exprimée par vecteur
Podergajs et al. Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF
WO2008086182A3 (fr) Utilisation de signatures de gène pour concevoir de nouveaux régimes de traitement de cancer
WO2008131191A8 (fr) Acides nucléiques hybridables avec des précurseurs des micro-arn de ceux-ci
WO2006028655A3 (fr) Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
EP2254897A4 (fr) Procédés, réactifs et nécessaires de détection de molécules d'acides nucléiques
MX388416B (es) Deteccion temprana de cancer de pulmon por clasificacion fenotipica por metilacion de adn de celulas derivadas de esputo
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980157378.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09834226

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 212979

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09834226

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载